ATL congrats on posting this public information. Questions:
Comment 1: For DC VAX L as a monotherapy, the 228% is the same as having 5 % alive for SOC and 13% alive for DC VAX L at 5 years. Right?
Comment 2 : 50% of the patients alive at 10 years is unprecedented in GBM.
Comment 3: Ok, it's better with the PD-1 inhibitor given neoadujuvantly for ndGBM; adjuvantly for rGBM. Right?
Comment 4: Looks like the MOS for rGBM combo patients will be 27 months.
ATLnsider
Re: None
Friday, October 28, 2022 11:48:36 AM
Post#
525614
of 525703
A doctor friend of mine, virtually attended the 10/26/2022 presentation by Dr. Linda Liau at the University of Pittsburgh. He confidentially shared 38 slides from the presentation with me. However, he said that Dr. Linda Liau and the University of Pittsburgh Department of Neurological Surgery do not want these slides released to the general public.
I will honor his request and I will not post these slides. However, I will make a few comments about the content of some of the slides:
(1) The DCVax-L Phase III trial results showed a significant increase of 228% in 5-Year overall survival (OS) for newly diagnosed GBM (ndGBM), and a increase of 217% in 30-Month survival for recurrent GBM (rGBM).
(2) Dr. Linda Liau presented slides that also showed some extraordinary OS results for the combination trials with DC Vaccine and other treatments. One slide was the combination with DC Vaccine plus poly-ICLC. The survival probability was about 50%, and the mOS was approaching 120 months or 10 years. This slide also showed Progression Free Survival (PFS) of almost 100 months (8.33 years).
(3) Two other slides showed that when a DC Vaccine is combined with a PD-1 inhibitor, for ndGBM it is better to treat with the PD-1 inhibitor on a neoadjuvant basis, and for rGBM, it is better to treat with the PD-1 inhibitor on an adjuvant basis
(4) For patients with rGBM, and treated with a DC Vaccine plus a PD-1 on an adjuvant basis, the mOS has not been reached yet, and it is approaching 800 days (26.67 months).
These combination results are spectacular, I know that some of the investors in NWBO do not fully understand or appreciate what they own. Some are looking forward to selling their shares at $2, $3, $5, $7, etc. That is their prerogative. Some want to sell the company at $20 per share. But, I believe the DCVax vaccine platform is truly transformative, and it is tumor agnostic, and should work to treat all or most solid tumor cancers, regardless of which organ the tumor is located in.
AI
